Ripretinib: First Approval

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

(2020) Jean-Yves Blay et al.   LANCET ONCOLOGY

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

(2019) Bryan D. Smith et al.   CANCER CELL

LBA87INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)

(2019) M von Mehren et al.   ANNALS OF ONCOLOGY

Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib

(2019) John Nemunaitis et al.   Future Oncology

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis

(2018) Mathias Schneeweiss et al.   HAEMATOLOGICA

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis

(2018) Mathias Schneeweiss et al.   HAEMATOLOGICA

Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies

(2016) Kjetil Søreide et al.   Cancer Epidemiology